Resident in JLABS incubator at LabCentral in Cambridge, MA , Vincere is structured around development of small molecule therapeutics to improve mitochondrial quality. Natural mechanisms of mitochondrial quality control decline with age, leading to the type of neurodegeneration seen in Parkinson's disease. Focused on developing disease-modifying therapies for Parkinson's disease, Vincere is anchored in a pipeline of molecular targets that emerged from its parent company, NeuroInitiative LLC - the latter having a patented computational discovery platform. Parkinsons disease affects 10 million people worldwide with no approved therapy to slow or stop the progressive neurodegeneration that underlies debilitating symptoms of the disease. The firm's singular focus is on addressing this unmet medical need through interventions that target key pathogenic mechanisms of Parkinson's disease.
